Wall Street brokerages predict that Apellis Pharmaceuticals Inc (NASDAQ:APLS) will post ($1.04) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Apellis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.11). Apellis Pharmaceuticals posted earnings of ($0.64) per share in the same quarter last year, which indicates a negative year over year growth rate of 62.5%. The firm is expected to announce its next earnings report on Tuesday, November 12th.
On average, analysts expect that Apellis Pharmaceuticals will report full year earnings of ($4.07) per share for the current fiscal year, with EPS estimates ranging from ($4.26) to ($3.77). For the next year, analysts anticipate that the company will report earnings of ($4.38) per share, with EPS estimates ranging from ($4.53) to ($4.23). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Apellis Pharmaceuticals.
Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Wednesday, July 31st. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.18).
Apellis Pharmaceuticals stock opened at $25.56 on Wednesday. Apellis Pharmaceuticals has a twelve month low of $11.45 and a twelve month high of $33.18. The stock’s fifty day simple moving average is $27.04 and its 200-day simple moving average is $23.82. The company has a current ratio of 8.67, a quick ratio of 8.67 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $1.47 billion, a P/E ratio of -10.92 and a beta of 0.68.
In other news, CFO Timothy Eugene Sullivan bought 11,699 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was purchased at an average price of $29.71 per share, for a total transaction of $347,577.29. Following the completion of the purchase, the chief financial officer now owns 11,699 shares in the company, valued at approximately $347,577.29. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Pascal Deschatelets sold 42,460 shares of the business’s stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $24.82, for a total transaction of $1,053,857.20. Insiders have sold 57,460 shares of company stock worth $1,454,807 in the last ninety days. Corporate insiders own 10.60% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Apellis Pharmaceuticals by 160.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,300 shares of the company’s stock worth $33,000 after purchasing an additional 800 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Apellis Pharmaceuticals during the second quarter worth $39,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Apellis Pharmaceuticals by 59.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,944 shares of the company’s stock worth $75,000 after purchasing an additional 1,099 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of Apellis Pharmaceuticals during the second quarter worth $103,000. Finally, SG Americas Securities LLC acquired a new position in shares of Apellis Pharmaceuticals during the first quarter worth $112,000. Hedge funds and other institutional investors own 63.44% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Featured Article: What does a hold rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.